In the APOLLO trial, first-line treatment with anlotinib plus penpulimab improved progression-free survival and overall survival when compared to sorafenib.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years of age and older and high-risk individuals aged 12-64 years.